Immunoreactivity of protamine preparations used to reverse heparin anticoagulation

U. A. Adourian, C. A. Hirshman, N Franklin Adkinson, M. E. Weiss

Research output: Contribution to journalArticle

Abstract

To determine if four commercially available intravenous protamine preparations differed in their ability to bind to human antiprotamine antibody, the sera of seven protamine-insulin-dependent diabetics who had experienced life-threatening reactions to intravenous protamine and whose sera contained a mean of 67.4 μg/ml (range, 16-200 μg/ml) of antiprotamine IgG antibody were evaluated. Each serum was preincubated with buffer and 0.0014 to 1.4 mg/ml of the four protamine preparations before addition to an agarose-based solid-phase radioimmunoassay using 125I-radiolabeled staph protein A as the detection protein. In the seven sera, the concentration of soluble protamine inhibiting 50% of protamine antibody (IC50) was determined by interpolating from points above and below 50% inhibition for each protamine preparation. No significant difference was found in the IC50 among the four different protamine preparations (P > 0.25; Kruskal-Wallis). The authors concluded that there is no significant difference in the immunoreactivity of the four commercial protamine preparations with human antiprotamine IgG antibody. Thus, there appears to be no advantage in using a particular intravenous protamine preparation based on immunoreactivity with human antiprotamine antibody.

Original languageEnglish (US)
Pages (from-to)328-331
Number of pages4
JournalAnesthesiology
Volume73
Issue number2
StatePublished - 1990

Fingerprint

Protamines
Heparin
Antibodies
Serum
Inhibitory Concentration 50
Immunoglobulin G
Staphylococcal Protein A
Sepharose
Radioimmunoassay
Buffers
Insulin

Keywords

  • allergy, anaphylaxis: protamine
  • blood, coagulation: heparin; protamine
  • diabetes mellitus
  • immune response

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Adourian, U. A., Hirshman, C. A., Adkinson, N. F., & Weiss, M. E. (1990). Immunoreactivity of protamine preparations used to reverse heparin anticoagulation. Anesthesiology, 73(2), 328-331.

Immunoreactivity of protamine preparations used to reverse heparin anticoagulation. / Adourian, U. A.; Hirshman, C. A.; Adkinson, N Franklin; Weiss, M. E.

In: Anesthesiology, Vol. 73, No. 2, 1990, p. 328-331.

Research output: Contribution to journalArticle

Adourian, UA, Hirshman, CA, Adkinson, NF & Weiss, ME 1990, 'Immunoreactivity of protamine preparations used to reverse heparin anticoagulation', Anesthesiology, vol. 73, no. 2, pp. 328-331.
Adourian, U. A. ; Hirshman, C. A. ; Adkinson, N Franklin ; Weiss, M. E. / Immunoreactivity of protamine preparations used to reverse heparin anticoagulation. In: Anesthesiology. 1990 ; Vol. 73, No. 2. pp. 328-331.
@article{0a8f7c6d5cf64f5798a132ca4931e817,
title = "Immunoreactivity of protamine preparations used to reverse heparin anticoagulation",
abstract = "To determine if four commercially available intravenous protamine preparations differed in their ability to bind to human antiprotamine antibody, the sera of seven protamine-insulin-dependent diabetics who had experienced life-threatening reactions to intravenous protamine and whose sera contained a mean of 67.4 μg/ml (range, 16-200 μg/ml) of antiprotamine IgG antibody were evaluated. Each serum was preincubated with buffer and 0.0014 to 1.4 mg/ml of the four protamine preparations before addition to an agarose-based solid-phase radioimmunoassay using 125I-radiolabeled staph protein A as the detection protein. In the seven sera, the concentration of soluble protamine inhibiting 50{\%} of protamine antibody (IC50) was determined by interpolating from points above and below 50{\%} inhibition for each protamine preparation. No significant difference was found in the IC50 among the four different protamine preparations (P > 0.25; Kruskal-Wallis). The authors concluded that there is no significant difference in the immunoreactivity of the four commercial protamine preparations with human antiprotamine IgG antibody. Thus, there appears to be no advantage in using a particular intravenous protamine preparation based on immunoreactivity with human antiprotamine antibody.",
keywords = "allergy, anaphylaxis: protamine, blood, coagulation: heparin; protamine, diabetes mellitus, immune response",
author = "Adourian, {U. A.} and Hirshman, {C. A.} and Adkinson, {N Franklin} and Weiss, {M. E.}",
year = "1990",
language = "English (US)",
volume = "73",
pages = "328--331",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Immunoreactivity of protamine preparations used to reverse heparin anticoagulation

AU - Adourian, U. A.

AU - Hirshman, C. A.

AU - Adkinson, N Franklin

AU - Weiss, M. E.

PY - 1990

Y1 - 1990

N2 - To determine if four commercially available intravenous protamine preparations differed in their ability to bind to human antiprotamine antibody, the sera of seven protamine-insulin-dependent diabetics who had experienced life-threatening reactions to intravenous protamine and whose sera contained a mean of 67.4 μg/ml (range, 16-200 μg/ml) of antiprotamine IgG antibody were evaluated. Each serum was preincubated with buffer and 0.0014 to 1.4 mg/ml of the four protamine preparations before addition to an agarose-based solid-phase radioimmunoassay using 125I-radiolabeled staph protein A as the detection protein. In the seven sera, the concentration of soluble protamine inhibiting 50% of protamine antibody (IC50) was determined by interpolating from points above and below 50% inhibition for each protamine preparation. No significant difference was found in the IC50 among the four different protamine preparations (P > 0.25; Kruskal-Wallis). The authors concluded that there is no significant difference in the immunoreactivity of the four commercial protamine preparations with human antiprotamine IgG antibody. Thus, there appears to be no advantage in using a particular intravenous protamine preparation based on immunoreactivity with human antiprotamine antibody.

AB - To determine if four commercially available intravenous protamine preparations differed in their ability to bind to human antiprotamine antibody, the sera of seven protamine-insulin-dependent diabetics who had experienced life-threatening reactions to intravenous protamine and whose sera contained a mean of 67.4 μg/ml (range, 16-200 μg/ml) of antiprotamine IgG antibody were evaluated. Each serum was preincubated with buffer and 0.0014 to 1.4 mg/ml of the four protamine preparations before addition to an agarose-based solid-phase radioimmunoassay using 125I-radiolabeled staph protein A as the detection protein. In the seven sera, the concentration of soluble protamine inhibiting 50% of protamine antibody (IC50) was determined by interpolating from points above and below 50% inhibition for each protamine preparation. No significant difference was found in the IC50 among the four different protamine preparations (P > 0.25; Kruskal-Wallis). The authors concluded that there is no significant difference in the immunoreactivity of the four commercial protamine preparations with human antiprotamine IgG antibody. Thus, there appears to be no advantage in using a particular intravenous protamine preparation based on immunoreactivity with human antiprotamine antibody.

KW - allergy, anaphylaxis: protamine

KW - blood, coagulation: heparin; protamine

KW - diabetes mellitus

KW - immune response

UR - http://www.scopus.com/inward/record.url?scp=0024988979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024988979&partnerID=8YFLogxK

M3 - Article

C2 - 2382853

AN - SCOPUS:0024988979

VL - 73

SP - 328

EP - 331

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 2

ER -